When regulations for reducing the risk of transmission of variant Creut'feldt-Jakob disease (vCJD) through blood transfusion were brought i…

Precautionary measures to reduce the theoretical risk of transmission of vCJD through blood or blood products were introduced in 1998 following advice from the UK Committee on Safety of Medicines (CSM) and the Spongiform Encephalopathy Advisory Committee (SEAC).There is no scientific evidence that vCJD can be transmitted in humans through blood or blood transfusion. Purely as precautionary measures, and to reduce the theoretical risk to the blood supply, plasma for the manufacture of blood products is currently obtained from non-UK sources (Germany and USA) and donated blood from UK donors is leucodepleted (white blood cells are removed).